E-602 + cemiplimab

E-602 + cemiplimab is an investigational combination therapy comprised of E-602, a first-in-class human sialidase enzyme therapeutic developed by Palleon Pharmaceuticals, and cemiplimab, an approved anti-PD-1 monoclonal antibody (marketed as Libtayo)[1][3][4][6]. E-602 is designed to enzymatically degrade immunosuppressive sialoglycans found on hypersialylated tumors and immune cells, effectively restoring antitumor immunity by reversing glyco-immune checkpoint–mediated suppression. Cemiplimab blocks PD-1, an immune checkpoint, to promote T-cell mediated immune response against cancer cells. The combination was evaluated in Phase 1/2 trials (GLIMMER-01) for patients with advanced, PD-(L)1-resistant solid tumors including melanoma, non-small cell lung cancer (NSCLC), and esophagogastric junction cancer. The combination achieved tumor desialylation, reduced pro-tumor macrophages (CD163+), increased cytokine levels, and showed early antitumor activity with no dose-limiting toxicities[1][2][4][6].

Brand names

Libtayo